These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Factors influencing the deaggregation of chymotrypsin-treated human platelets aggregated by fibrinogen. Kinlough-Rathbone RL; Mustard JF; Packham MA; Harfenist EJ Thromb Haemost; 1983 Jun; 49(3):196-8. PubMed ID: 6410532 [TBL] [Abstract][Full Text] [Related]
9. Binding of aggregated immunoglobulins to the human platelet Fc receptors: a mechanism of platelet to platelet bridging. Parbtani A; Clark WF; Caveney A; Reid B Thromb Haemost; 1987 Dec; 58(4):966-70. PubMed ID: 3127922 [TBL] [Abstract][Full Text] [Related]
10. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN. Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653 [TBL] [Abstract][Full Text] [Related]
11. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents. Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of thrombin-degranulated human platelets: development of a method that does not use proteolytic enzymes for deaggregation. Kinlough-Rathbone RL; Packham MA; Guccione MA; Richardson M; Harfenist EJ; Mustard JF Thromb Haemost; 1991 Apr; 65(4):403-10. PubMed ID: 2057923 [TBL] [Abstract][Full Text] [Related]
15. Fibrinogen-independent aggregation and deaggregation of human platelets: studies in two afibrinogenemic patients. Cattaneo M; Kinlough-Rathbone RL; Lecchi A; Bevilacqua C; Packham MA; Mustard JF Blood; 1987 Jul; 70(1):221-6. PubMed ID: 3109523 [TBL] [Abstract][Full Text] [Related]
16. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data. Maayani S; Tagliente TM; Schwarz T; Craddock-Royal B; Alcala C; Marrero G; Martinez R Platelets; 2001 Aug; 12(5):279-91. PubMed ID: 11487380 [TBL] [Abstract][Full Text] [Related]
17. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Gachet C; Cazenave JP; Ohlmann P; Bouloux C; Defreyn G; Driot F; Maffrand JP Biochem Pharmacol; 1990 Dec; 40(12):2683-7. PubMed ID: 2175608 [TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Weber AA; Reimann S; Schrör K Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233 [TBL] [Abstract][Full Text] [Related]
19. Association of fibrinogen with human platelets pretreated with chymotrypsin or aggregated with ADP or thrombin: an immunocytochemical study. Suzuki H; Kinlough-Rathbone RL; Packham MA; Yamazaki H; Mustard JF Br J Exp Pathol; 1989 Aug; 70(4):479-88. PubMed ID: 2765399 [TBL] [Abstract][Full Text] [Related]
20. Contrasting effects of thrombin and the thrombin receptor peptide, SFLLRN, on aggregation and release of 14C-serotonin by human platelets pretreated with chymotrypsin or serratia marcescens protease. Kinlough-Rathbone RL; Perry DW; Packham MA Thromb Haemost; 1995 Jan; 73(1):122-5. PubMed ID: 7740483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]